6533b836fe1ef96bd12a15d9
RESEARCH PRODUCT
An elongation factor-like protein (EF-Tu) elicits a humoral response in infiltrating ductal breast carcinomas: an immunoproteomics investigation.
Christelle-lemaitre GuillierLauriane KuhnPhilippe HammannBechr HamritaHela Ben NasrKarim ChahedA. ChaiebHedi Khairisubject
ProteomicsAntibodies NeoplasmClinical BiochemistryPeptide Elongation Factor TuProteomicsImmunoproteomicsSerologyImmune systemBreast cancerAntigenAntigens NeoplasmCell Line TumormedicineHumansSerologic TestsbiologyCarcinoma Ductal BreastCancerGeneral Medicinemedicine.diseaseImmunity HumoralCase-Control StudiesImmunoglobulin GImmunologybiology.proteinFemaleAntibodydescription
Abstract Objectives In the current study, we have used an immunoproteomics approach to identify proteins that commonly elicit a humoral response in patients with infiltrating ductal carcinomas of the breast. Design and methods Sera obtained at the time of diagnosis from 40 patients with invasive breast cancer and 42 healthy controls were screened for the presence of IgG antibodies to MCF-7 cell line proteins using a serological proteomics-based approach. Results An immunoreactive protein detected in sera from 21 of 40 patients was isolated and subsequently identified as elongation factor-Tu. Conclusions The immunoproteomic approach implemented here offers a powerful tool for determining novel tumor antigens that induce a humoral immune response in cancer patients. From our findings, the immunoreactive EF-Tu protein and/or the related circulating antibodies may display clinical usefulness as potential diagnostic markers and provide a means for a better understanding of the molecular mechanisms underlying breast cancer development.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-03-25 | Clinical biochemistry |